Show simple item record

dc.contributor.authorRuiz-Patinõ, Alejandro
dc.contributor.authorArrieta, Oscar
dc.contributor.authorCardona, Andres
dc.contributor.authorMartín, Claudio Marcelo
dc.contributor.authorRaez, Luis Estuardo
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorBarron, Feliciano
dc.contributor.authorRicaurte, Luisa María
dc.contributor.authorBravo-Garzón, María A.
dc.contributor.authorMas, Luis A.
dc.contributor.authorCorrales, Luis
dc.contributor.authorRojas, Leonardo
dc.contributor.authorLupinacci, Lorena
dc.contributor.authorPerazzo, Florencia
dc.contributor.authorBas, Carlos Arturo
dc.contributor.authorCarranza, Omar E.
dc.contributor.authorPuparelli, Carmen
dc.contributor.authorRizzo, Miguel M
dc.contributor.authorRuiz, Rossana
dc.contributor.authorRolfo, Christian
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez, July F.
dc.contributor.authorVargas, Carlos Alberto
dc.contributor.authorCarranza, Hernán
dc.contributor.authorOtero, Jorge Miguel
dc.contributor.authorPino, Luis Eduardo
dc.contributor.authorOrtíz, Carlos
dc.contributor.authorLaguado, Paola
dc.contributor.authorRosell, Rafael Costa
dc.date.accessioned2020-03-09T15:30:12Z
dc.date.available2020-03-09T15:30:12Z
dc.identifier.issn1759-7706spa
dc.identifier.urihttp://hdl.handle.net/20.500.12495/2022
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherWiley-Blackwellspa
dc.relation.ispartofseriesThoracic Cancer, 1759-7706, Vol. 11, Nro. 2, 2020, p. 353-361spa
dc.relation.urihttps://onlinelibrary.wiley.com/doi/full/10.1111/1759-7714.13272spa
dc.rightsAttribution 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)spa
dc.typearticlespa
dc.type.localartículospa
dc.subject.decsEstadificación de neoplasiasspa
dc.subject.decsSistema nervioso centralspa
dc.subject.decsEstudios de cohortesspa
dc.subject.keywordsAdultspa
dc.subject.keywordsImmunotherapyspa
dc.subject.keywordsLung neoplasmsspa
dc.identifier.doihttps://doi.org/10.1111/1759-7714.13272spa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.publisher.journalThoracic Cancerspa
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame: Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.cospa
dc.title.translatedImmunotherapy at any line of treatment improves survival in patients with advanced metastatic non‐small cell lung cancer (NSCLC) compared with chemotherapy (Quijote‐CLICaP)
dc.description.abstractenglishBackground: To compare survival outcomes of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who received immunotherapy as first-, second- or beyond line, versus matched patients receiving standard chemotherapy with special characterization of hyperprogressors. Methods: A retrospective cohort study of 296 patients with unresectable/metastatic NSCLC treated with either, first-, second-, third- or fourth-line of immunotherapy was conducted. A matched comparison with a historical cohort of first-line chemotherapy and a random forest tree analysis to characterize hyperprogressors was conducted. Results: Median age was 64 years (range 34–90), 40.2% of patients were female. A total of 91.2% of patients had an Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1. Immunotherapy as first-line was given to 39 patients (13.7%), second-line to 140 (48.8%), and as third-line and beyond to 108 (37.6%). Median overall survival was 12.7 months (95% CI 9.67–14 months) and progression-free survival (PFS) of 4.27 months (95% CI 3.97–5.0). Factors associated with increased survival included treatment with immunotherapy as first-line (P < 0.001), type of response (P < 0.001) and PD-L1 status (P = 0.0039). Compared with the historical cohort, immunotherapy proved to be superior in terms of OS (P = 0.05) but not PFS (P = 0.2). A total of 44 hyperprogressors were documented (19.8%, [95% CI 14.5–25.1%]). Leukocyte count over 5.300 cells/dL was present in both hyperprogressors and long-term responders. Conclusions: Patients who receive immune-checkpoint inhibitors as part of their treatment for NSCLC have better overall survival (OS) compared with matched patients treated with standard chemotherapy, regardless of the line of treatment.spa
dc.rights.localAcceso abiertospa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf304spa
dc.date.issued2020


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as Attribution 4.0 International